Prognostic effects of TP53 mutations have been studied extensively; however, no concordance between the outcomes of individual studies was observed [19,24,25,26,27,28], possibly because the histological subtypes associated with different OS were combined as one cohort of either LGG or glioma, particularly in survival studies, which led to discordant results. This evidence concerns the gene TP53 and central nervous system cancer.